Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Feb;171(4):931-5.
doi: 10.1111/bph.12499.

Midkine and multiple sclerosis

Affiliations
Review

Midkine and multiple sclerosis

Hideyuki Takeuchi. Br J Pharmacol. 2014 Feb.

Abstract

Multiple sclerosis (MS) is an autoimmune neurological disease characterized by inflammatory demyelination with subsequent neuronal damage in the CNS. MS and its animal model, experimental autoimmune encephalomyelitis (EAE), have been thought as autoreactive Th1 and Th17 cell-mediated diseases. CD4(+) CD25(+) FoxP3(+) regulatory T-cell (Treg) plays a pivotal role in autoimmune tolerance, and tolerogenic dendritic cells (DCreg) drive the development of inducible Treg cells. Thus, a dysfunction in the development of Treg and DCreg leads to the development of autoimmune diseases. However, the factors that regulate Treg and DCreg are largely unknown. We recently showed that removal of midkine (MK) suppressed EAE due to an expansion of the Treg cell population as well as a decrease in the numbers of autoreactive Th1 and Th17 cells. MK decreased the Treg cell population by suppressing the phosphorylation of STAT5, which is essential for the expression of Foxp3, the master transcriptional factor of Treg cell differentiation. Furthermore, MK reduces the DCreg cell population by inhibiting the phosphorylation of STAT3, which is critical for DCreg development. Blockade of MK signalling by a specific RNA aptamer significantly elevated the population of DCreg and Treg cells and ameliorated EAE without detectable adverse effects. Therefore, the inhibition of MK may provide an effective therapeutic strategy against autoimmune diseases including MS.

Linked articles: This article is part of a themed section on Midkine. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue-4.

Keywords: aptamer; experimental autoimmune encephalomyelitis; midkine; multiple sclerosis; regulatory T-cell; tolerogenic dendritic cell.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MK negatively regulates autoimmune tolerance via suppression of DCreg development and Treg expansion. IL-10 signalling differentiates dendritic cells into DCreg via STAT3 activation. Then, cell-to-cell interaction with DCreg and IL-2 signalling differentiates naïve T-cells into CD4+CD25+Foxp3+Treg via STAT5 activation. MK activates tyrosine phosphatase SHP-2 that is a negative regulator of STAT3 and STAT5, leading to suppression of DCreg development and Treg expansion. Therefore, MK is a critical suppressor of autoimmune tolerance. In other words, blockade of MK effectively suppresses autoimmunity by enhancing DCreg development and Treg expansion.

Similar articles

Cited by

References

    1. Baecher-Allan C, Hafler DA. Suppressor T cells in human diseases. J Exp Med. 2004;200:273–276. - PMC - PubMed
    1. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006;441:235–238. - PubMed
    1. Brody EN, Gold L. Aptamers as therapeutic and diagnostic agents. J Biotechnol. 2000;74:5–13. - PubMed
    1. Codarri L, Gyulveszi G, Tosevski V, Hesske L, Fontana A, Magnenat L, et al. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011;12:560–567. - PubMed
    1. Diotti RA, Nakanishi A, Clementi N, Mancini N, Criscuolo E, Solforosi L, et al. JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes. Clin Dev Immunol. 2013;2013:967581. - PMC - PubMed

Publication types